Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSC in Adults with Autism Spectrum Disorder
NCT04484077Phase 1Completed
- Sponsor
- Joanne Kurtzberg
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in Autism Spectrum Disorder (ASD), sponsored by Joanne Kurtzberg. Primary endpoints: Incidence of infusion reactions at 10 days, Incidence of product-related infections at 12 months and 3 more. Started Jan 2022; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04484077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484077.